Cyclophosphamide Loading and Controlled Release in MIL-100(Fe) as an Anti-breast Cancer Carrier: In vivo In vitro Study

Background: Biocompatible MIL-100 (Fe), a metal organic framework material, has recently attracted increasing attention in biomedical engineering. The high surface area, pore volume, and accessible Lewis acid sites make MIL-100 (Fe) a proper candidate for hydrophobic anticancer drug loading and storage. In this study, a novel investigation of cyclophosphamide (CP) -loaded MIL-100(Fe) (MIL- 100(Fe)/CP) and a simulation of drug loading at a molecular level is presented. Methods: This research used a facile synthesis method to prepare MIL-100(Fe), which addresses the high temperature and pressure challenges of synthesis methods. MIL-100(Fe) and MIL-100(Fe)/CP were characterized using x-ray diffraction (XRD), Brunauer–Emmett–Teller (BET), Fourier transform infrared (FTIR), and field emission scanning electron microscopy (FESEM). Results: The carriers' drug loading and release behavior are determined by using UV-visible spectrophotometry. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay is applied to examine the biocompatibility and the anticancer effect of MIL-100(Fe)/CP on the human breast cancer cell line (MCF-7). Conclusion: In vivoantitumor experiments and histological observation reveal inhibition properties of MIL-100(Fe)/CP on the tumor cells. MIL-100(Fe)/CP, with 37.41% drug payload, represents impressive antitumor activity.